Member Info for grizzlyb

Hopefully the placing at 70p (a 28% discount to market price) 5 months ago is enough of a muck up for the time being.

Hi Phil, I read this article yesterday morning too whilst trying to find out a bit more about Codiak. I certainly feel ReNeuron's exosomes, being derived from stem cells already in human clinical trials, and also the ability to produce at an industrial scale, puts us well ahead of plenty of others in the field. Seems we are far under the radar.

http://www.reneuron.com/wp-content/uploads/ReNeuron-Corporate-Presentation-April-2021.pdf

https://patents.google.com/patent/WO2021028674A1/en?assignee=Reneuron&oq=Reneuron&sort=new&clustered=true

The exosome project is evolving nicely. I imagine the latest commercial collaboration would be on a 50% ownership of the eventual product inline with the previous agreements

As an aside, this patent was published last month. Lots of interesting things going on at ReNeuron.

Remaining with the company until the end of May suggests the search for his replacement may not have started yesterday. Although if it did, they'd have had an extra 6 hours to get things started if targeting the US.

Where does it say , Balerno? Clinicaltriaks.gov still says not yet recruiting.

Agreed. AIM is viewed as risky by many whilst NASDAQ has Tesla, Facebook, etc. I know where I'd rather be.

Or at least trying to.

Treeshakers, we already have one partner with deep pockets for hRPC - Fosun.

https://vimeo.com/498431522

https://www.proactiveinvestors.co.uk/companies/amp/news/938840?__twitter_impression=true

Morning Phil. Estimated primary completion date on clinical trials.gov is May 2021 and I believe the patients already treated will continue to be followed up according to the trial protocol. Not sure how many patients that is though and I guess no guarantee they will have to update, but it'd make sense to provide an update around that time.

Not sure if already poated...ReNeuron are taking part in this event later this month: https://www.lsegissuerservices.com/spark/edison-open-house-global-healthcare-2021

Also to note for Q2, Phase IIb stroke therapy (Pisces III) update due in May. Little talked about but potentially game-changing.

And in 2012, not much has changed! https://www.standard.co.uk/business/city-spy-reneuron-gets-on-investors-nerves-6550521.html

Perhaps MH shouldn't rush fundraising.

Sorry sent before I'd finished! I'm sure they'll rapidly assign value to exosomes once we have proof of concept. £190 million seems a bit low for everything that's going on, although the market disagrees as usual. Heading in the right direction though!

I'm sure they'll rapidly assign a value if we get proof of concept.

Recent analyst conference call suggested we won't get an RP update until results are announced at a conference.

Despite being open label, board would have preferred not to have had to announce results so frequently, but the low number of patients meant individual results were material.

I'd have thought they could have argued from the start that the very nature of a clinical study means there will be a gradual increase in data and that, and the length of the trial, are known features so it's only the end result that's material. But perhaps not.

A capital raise at 70p clearly is a failure for MH, giving previous pricing and competitors' fundraising abilities, there's no other way to describe it. Unless it was intentionally low, then I suppose it was a resounding success. I'd speculate that announcement of a NASDAQ listing would have bolstered the price well beyond 70p, allowing for a a sensible fundraising.

Cheers Phil.

Indeed, a clear pathway presumably a demand of some of the larger investors.